USPTO serial 79269640
THORACOFLO
Reviewed by CopyMark Law Group
Reg. 6160714Status 739Renewal
- Filing date
- Status date
- Registration date
- Sep 29, 2020
- Examiner
- FITZSIMONS, MICHAEL R
- Law office
- Historical data usage
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with THORACOFLO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $399*
Plus Government fees of $425
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Megan E. Fink
Megan E. Fink Bodman PLC201 South Division Street, Suite 400Ann Arbor, MI 48104United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 010 | Surgical, medical, dental and veterinary apparatus and instruments; artificial vascular grafts, artificial stent grafts, artificial thoracic, thoracoabdominal and abdominal stent grafts, surgical hybrid stent graft for treatment of thoracoabdominal aortic aneurysms, stents, patches for repair and reconstruction of internal tissue, and vascular prostheses; surgical implants comprising artificial materials; suture materials; grafts made primarily of artificial materials being patches for repair and reconstruction of internal tissue; implantable medical systems comprised of artificial endovascular stent grafts; implantable medical devices namely, artificial endovascular stent grafts; artificial vascular grafts; artificial branched vascular grafts; artificial endovascular grafts; surgical graft materials namely, artificial endovascular grafts, artificial endovascular grafts; medical systems, namely, systems for use in artificial organ support; medical devices for measuring blood sugar for medical purposes; surgical systems namely stent delivery systems; surgical devices; devices comprising an artificial vascular graft and a stent; devices comprising an artificial vascular graft, a stent and a delivery system; medical systems and medical devices in the nature of surgical implants comprising artificial material and associated surgical instrument sets for use in thoracoabdominal procedures; medical systems and medical devices in the nature of surgical implants comprising artificial material and associated surgical instrument sets for use in aortic arch procedures; medical systems and medical devices in the nature of surgical implants comprising artificial material and associated surgical instrument sets for use in endovascular procedures; thoracic stents; artificial thoracic stent grafts; thoracoabdominal stents; artificial thoracoabdominal stent grafts; artificial stent grafts; artificial stent graft systems; artificial stent graft devices; artificial stent graft systems and surgical devices comprising more than one component; artificial stent graft systems and surgical devices comprising components of more than one stent graft; artificial stent graft systems and surgical devices comprising components of more than one type of stent graft; devices comprising an artificial graft and stent joined together and compacted into a delivery system; artificial thoracic stent graft systems; artificial thoracic stent graft devices; artificial thoracoabdominal stent graft systems; artificial thoracoabdominal stent graft devices; delivery systems for artificial stents and grafts; delivery systems for artificial stent graft systems and artificial stent graft devices; medical systems, namely, minimally invasive devices for aneurysm repair; medical devices, namely, minimally invasive devices for aneurysm repair; medical systems, namely, minimally invasive devices for thoracoabdominal aortic aneurysm ('TAAA') repair; medical devices, namely, minimally invasive devices for thoracoabdominal aortic aneurysm ('TAAA') repair; cardiac valves for surgical prostheses; cardiac valve replacement systems namely, artificial cardiac valves; artificial heart valves; artificial heart valve conduits; artificial cardiac patches; artificial vascular patches; parts and fittings for all of the aforementioned goods | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 23, 2026 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Oct 23, 2026 | C75A | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Oct 19, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Sep 16, 2026 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Mar 20, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 20, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 20, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 20, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 20, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 29, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Feb 13, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 22, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 22, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 29, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Sep 29, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 14, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 14, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 24, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 9, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 15, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 14, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 14, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 14, 2019 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 22, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 22, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 1, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 31, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 22, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 18, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 18, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 17, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |